1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. Syk

Syk

Syk (Spleen tyrosine kinase) is an enzyme which in humans is encoded by the SYK gene. Syk, along with Zap-70, is a member of the Syk family of tyrosine kinases. Syk is known to have a crucial role in adaptive immune receptor signalling. Recent reports indicate that Syk also mediates other, unexpectedly diverse biological functions, including cellular adhesion, innate immune recognition, osteoclast maturation, platelet activation and vascular development. Syk is activated by C-type lectins and integrins, and activates new targets, including the CARD9-Bcl-10-MALT1 pathway and the NLRP3 inflammasome. Syk has a crucial role in autoimmune diseases and haematological malignancies.

Syk Related Products (20):

Cat. No. Product Name Effect Purity
  • HY-15968
    Entospletinib Inhibitor 99.86%
    Entospletinib (GS-9973) is an orally bioavailable, selective Syk inhibitor with an IC50 of 7.7 nM.
  • HY-15999
    Cerdulatinib Inhibitor 99.00%
    Cerdulatinib (PRT062070) is a dual JAK and SYK inhibitor with IC50s of 12, 6, 8 and 32 for JAK1, 2, 3 and SYK, respectively.
  • HY-100867A
    TAK-659 hydrochloride Inhibitor 99.69%
    TAK-659 hydrochloride is a potent, selective and orally available spleen tyrosine kinase (Syk) inhibitor with an IC50 of 3.2 nM.
  • HY-13518
    Piceatannol Inhibitor 98.10%
    Piceatannol is a selective inhibitor of protein tyrosine kinase Syk.
  • HY-15323
    PRT062607 Hydrochloride Inhibitor 98.90%
    PRT062607 Hydrochloride (P505-15 Hydrochloride) is a highly specific and potent inhibitor of purified Syk (IC50 1-2 nM).
  • HY-109091
    Lanraplenib Inhibitor
    Lanraplenib (GS-9876) is a highly selective and oral SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib (GS-9876) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.
  • HY-100867
    TAK-659 Inhibitor
    TAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC50 of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL).
  • HY-13038
    Fostamatinib Disodium Inhibitor 98.79%
    Fostamatinib Disodium (R788 Disodium), a prodrug of the active metabolite R406, is a potent Syk inhibitor with IC50 of 41 nM.
  • HY-12067
    R406 Inhibitor
    R406 is a competitive Syk inhibitor for ATP binding with a Ki of 30 nM, potently inhibits Syk kinase activity in vitro with an IC50 of 41 nM, measured at an ATP concentration corresponding to its Km value.
  • HY-14985
    BAY 61-3606 dihydrochloride Inhibitor 98.21%
    BAY 61-3606 dihydrochloride is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM an IC50 of 10 nM. BAY 61-3606 dihydrochloride reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell. BAY 61-3606 dihydrochloride induces a large decrease of Syk phosphorylation in K-rn cell lysates. Bay 61-3606 dihydrochloride sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells.
  • HY-11108
    R406 free base Inhibitor 99.25%
    R406 free base is a potent Syk inhibitor with IC50 of 41 nM, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3.
  • HY-13038B
    Fostamatinib disodium hexahydrate Inhibitor 98.87%
    Fostamatinib disodium hexahydrate (R788 disodium hexahydrate), a prodrug of the active metabolite R406, is a potent Syk inhibitor with IC50 of 41 nM.
  • HY-12974
    PRT-060318 Inhibitor 98.01%
    PRT-060318 (PRT318) is a novel selective inhibitor of the tyrosine kinase Syk with an IC50 of 4 nM.
  • HY-16902
    RO9021 Inhibitor 98.89%
    RO9021 is an orally bioavailable, novel ATP-competitive inhibitor of SYK, with an average IC50 of 5.6 nM.
  • HY-103018
    Gusacitinib Inhibitor 99.41%
    Gusacitinib (ASN-002) is a potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 values of 5-46 nM.
  • HY-78263
    MNS Inhibitor 99.23%
    MNS is a potent and selective inhibitor of Src and Syk tyrosine kinases.
  • HY-16420
    R112 Inhibitor 99.95%
    R112 is an ATP-competitive inhibitor of Syk kinase with a Ki of 96 nM. R112 inhibits Syk kinase activity with an IC50 of 226 nM.
  • HY-76474
    BAY 61-3606 Inhibitor
    BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM and an IC50 of 10 nM. BAY 61-3606 reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell. BAY 61-3606 induces a large decrease of Syk phosphorylation in K-rn cell lysates. Bay 61-3606 sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells.
  • HY-13038A
    Fostamatinib Inhibitor
    Fostamatinib (R788), a prodrug of the active metabolite R406, is a potent Syk inhibitor with IC50 of 41 nM.
  • HY-15322
    PRT062607 Inhibitor
    PRT062607(P505-15; PRT-2607; BIIB-057) is a highly specific and potent inhibitor of Syk with IC50 of 1-2 nM; >80-fold selective for Syk than Fgr, Lyn, FAK, Pyk2 and Zap70.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.